What is the real-world lead time from Xi’an to South Africa in winter?

The particulars: Xi’an · South Africa.

I want to understand what this actually establishes, as opposed to what it is being used to imply.

My concern is that I am being invited to draw a conclusion the data does not support.

What does this actually establish, and what does it not?

It helps to be literal here: start from what "research use only" actually means, because most of the downstream questions are answered by it. It means no release testing, no pharmacovigilance, no regulatory obligation to you, and no recourse.

What a verification listing at VendorInvestigate or a rating at PeptideMeter actually evidences is that some process was applied — which is more than nothing and considerably less than an audit. The useful question is what the process consists of and whether its inputs are independently obtained samples or vendor-supplied ones.

Lot-to-lot content variation of nine per cent between two nominally identical lots, both within a stated specification, is the single most common finding in independent testing and the least discussed. It is not fraud; it is the consequence of a fill process controlled to a tolerance rather than to a target. It is also the reason a per-lot content assay is worth more than a per-supplier reputation.

Regulatory positions on personal importation are published: the relevant frameworks are the US FDA’s personal importation policy in its Regulatory Procedures Manual, the UK MHRA’s guidance on importing medicines for personal use, and the equivalent national provisions in the EU member states and Australia’s Therapeutic Goods Administration personal importation scheme. They differ materially from each other.

The caveat is that none of this makes an unapproved product safe or lawful to use. It reduces one category of uncertainty — what is in the vial — and leaves every other category untouched.

Assume no recourse and plan accordingly. That assumption is both prudent and, in this context, accurate.